

Press release  
30 March 2009  
Göteborg, Sweden

## Vitrolife withdraws its offer for MediCult

With reference to its voluntary exchange offer of 3 February 2009 (as extended) to purchase the shares in MediCult a/s (OSE: MEC), Vitrolife hereby announce that as of the expiry of the offer on 27 March 2009 at 17:30 CET, the level of acceptances received had not reached 90 per cent of the shares in MediCult a/s. As a result, the conditions for the offer have not been fulfilled and the offer has been withdrawn.

### Contact persons

Contact persons at Vitrolife with respect to the Offer:

Patrik Tigerschiöld, Chairman of the Board	tel. +46 707 77 71 90
Dr. Magnus Nilsson, CEO	tel. +46 31 721 80 61

---

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

Vitrolife is required under the Swedish Securities Market Act to publish the information in this press release. The information was submitted for publication on 30 March 2009 at 4.30 pm CET.